AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer – in one of the most ...
Hosted on MSN2mon
Daiichi Sankyo doses first subject in Phase III AML therapy trialDaiichi Sankyo oncology clinical development global head Mark Rutstein said: “Preliminary data have shown promising results for Vanflyta in patients with FLT3-ITD negative acute myeloid ...
Trump tariffs on chips and drugs would hit U.S. allies in Asia Worldcategory· January 28, 2025 The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's ...
TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback